key: cord-0816955-87ctzhgp
authors: Kankaria, Rohan; Sanina, Cristina; Gabr, Mohamed; Wiley, Jose; Bortnick, Anna E.
title: Extracardiac Prothrombotic Effects of COVID-19
date: 2022-03-29
journal: Cardiol Clin
DOI: 10.1016/j.ccl.2022.03.008
sha: 6ef0d2e0eb03b79055d765fabb87d0267cc3af4f
doc_id: 816955
cord_uid: 87ctzhgp

COVID-19 infection triggers a heightened inflammatory response which in turn, increases thrombosis and thromboembolism. Microvascular thrombosis has been detected in various tissue beds which may account for some of the multi-system organ dysfunction associated with COVID-19. Additional research is needed to understand which prophylactic and therapeutic drug regimens are best for the prevention and treatment of thrombotic complications of COVID-19.

The COVID-19 pandemic has had devastating effects on global health, with greater than 220 million cases and >4 million deaths since January 2020 reported to the World Health Organization. 1, 2 Highly transmissible variants risk further spread. In addition to acute respiratory failure, COVID-19 has been linked to arterial and venous thrombosis, especially in those with severe disease. 3 In this review, we summarize data on COVID-19 thrombotic complications ( Figure 1 ), delineating the micro-and macrovascular complications that can lead to acute and chronic organ dysfunction and treatment protocols that could lessen the burden of thrombosis.

J o u r n a l P r e -p r o o f Viral pulmonary diseases elaborate inflammatory cytokines which have prothrombotic effects in the vasculature of critically ill patients. 4 SARS-CoV-2, the virus causing COVID-19 illness, invades endothelial cells causing local complement activation and inflammation which leads to microvascular thrombosis. [5] [6] [7] Amplification of inflammatory and microvascular insult eventually leads to widespread macrovascular thrombotic injury, with COVID-19 patients experiencing both venous and arterial thrombosis.

Widespread microthrombosis affecting various organ systems is a potential mechanism for long-term sequalae after recovery from COVID-19 which requires investigation. COVID-19 patients appear to experience subclinical microvascular thrombosis prior to developing gross venous or arterial events. 5 One study examining 13 critically ill COVID-19 patients on mechanical ventilation detected sublingual microthrombi using capillaroscopy, despite none of the patients meeting criteria for diffuse intravascular coagulation. 8 Platelet-rich thrombi have been detected in the pulmonary, renal, cardiac, and hepatic microvasculature, with histopathology indicating increased presence megakaryocytes, a finding suggestive of a cytokine-mediated thrombosis. 9

Pulmonary injury in COVID-19 patients may extend beyond diffuse alveolar disease from acute respiratory distress syndrome. Autopsy reports, though limited, demonstrate extensive complement deposition and diffuse microthrombi predominantly in the septal capillaries. 7, 9, 10 In a case series of 31 COVID-19 patients, 25% of those with elevated D-dimer J o u r n a l P r e -p r o o f levels (>1000 ng/mL) had pulmonary perfusion deficits on computed tomography angiography, but only 2 were noted to have gross pulmonary embolism (PE). 10 

The incidence of acute kidney injury (AKI) in patients with COVID-19 is high, from 9-27% in retrospective studies and similar to patients who have other pneumonias. [11] [12] [13] Many factors contribute to AKI, but findings from biopsy studies suggest that it is compounded by microvascular thrombosis. Autopsies from 6 patients showed widespread acute tubular necrosis and glomerular capillary damage from complement activity. 11 Viral inclusions were found in kidney cells supporting direct infection as a mechanism of localized cell death and inflammatory response. Renal perfusion deficits have been observed on imaging, as well. 10 Renal biopsy studies, though limited, demonstrate thrombotic microangiopathy, complement deposition in the mesangial space, fibrin thrombi in the glomeruli, and cortical necrosis in patients with severe AKI. 14, 15 Hypercoagulability, defined as a low ADMATS13/VWF antigen ratio, was strongly associated with worsened AKI and severe illness, further supporting renal microthrombosis as a contributory factor to the high incidence of AKI in patients with COVID-19. 16

There have been multiple case reports of dermatologic and ophthalmologic microvascular thrombosis. 7, [17] [18] [19] Patients with pulmonary hemorrhage on autopsy were also found to have J o u r n a l P r e -p r o o f complement deposition in the dermal microvasculature. 7 Inflammation of the dermal microvasculature (chilblains) has been reported. 17 Interestingly, complement deposition in skin has also been documented from patients with COVID-19 who did not exhibit pulmonary deficits or obvious skin findings. 7 There is a singular report of retinal vasculitis in a child, as well as an autopsy series demonstrating ocular endothelial cell damage and fibrin microvascular thrombi in severe COVID-19 illness. 17,18 However, a larger retrospective cohort study found no significant difference when comparing COVID-19 patients and controls for vascular perfusion in the superficial or deep vascular plexus of the eye, suggesting that it is possible that microthrombi may dissipate with resolution of disease or that the eye may be spared in many instances. 19

COVID-19 illness has been associated with myocardial infarction (MI), myocarditis, and cardiomyopathy (reviewed in Chapter 5). The incidence of MI in patients with COVID-19 has been estimated to range from 0.33-8%. 20,21 COVID-19-associated ST-elevation myocardial infarction (STEMI) has been well described and is associated with higher mortality compared to STEMI in patients without COVID-19 infection. 22 

COVID-19 illness is associated with acute liver injury. Proposed mechanisms of injury are: systemic inflammation, hepatic ischemia, drug toxicity, and hepatic microthrombi, which have been seen on autopsy. 9,24 A series of postmortem liver biopsies in COVID-19 patients, without preexisting liver disease or clinical signs of hepatic failure, found that > 50% had sinusoidal microthrombi and those individuals had 10-fold higher liver enzyme levels than those who did not have microthrombi. 25 Liver involvement in severe COVID-19 infection was confirmed in a second autopsy series demonstrating hepatic steatosis and elevated megakaryocytes in hepatic sinusoids, which were associated with systemically elevated D-dimer and liver enzyme levels in those individuals. 26 Importantly, two types of microthrombi have been described in hepatic sinusoids: sinusoidal erythrocyte aggregation (SEA) and platelet microthrombi (PMT). PMT thrombosis was associated with significant steatosis as compared to COVID-19 patients without sinusoidal microthrombosis (79% vs. 35%, p = 0.02). 25 Both PMT and SEA thrombosis were associated with significant neutrophil accumulation in the hepatic sinusoids, illustrating the inflammatory component of microthrombotic injury. Compared to SEA, patients with PMT thrombosis were found to have increased incidence of liver injury. 25 Conversely, a third large autopsy series found minimal microthrombi, with 50% having mild hepatitis and 75% with macrovesicular steatosis. Hepatic vascular findings were limited to scarce non-diffuse vascular abnormalities with 6 patients showing signs of veno-occlusive J o u r n a l P r e -p r o o f disease and 5 patients showing signs of arteriolar muscular hyperplasia. 27 Of note, in all three autopsy studies, steatosis was not associated with obesity or diabetes, suggesting that hepatic steatosis in these decedents of COVID-19 was not secondary to nonalcoholic fatty liver disease, but more likely a consequence of inflammation. 25

The mechanism of macrovascular thrombosis appears to be an extension of the proposed mechanisms delineating microvascular thrombosis. Pro-inflammatory mediated cytokine release and direct endothelial damage activate the coagulation cascade leading to wide-spread macrovascular thrombosis, including PE, deep vein thrombosis (DVT), stroke, and MI. 28

COVID-19 has been associated with an increased incidence of PE ranging from 8.3-23%, depending on the severity of illness, based on retrospective studies. [29] [30] [31] In comparison, the incidence of any venous thrombosis in the general population is 0.1%. 32 There is conflicting evidence that obesity predisposes to developing PE in the context of COVID-19 and it may depend on the severity of illness. Male sex and concomitant cardiovascular disease are potentially predisposing factors, as well. 31 Multiple studies indicate that patients with PE have higher D-dimer levels when compared to COVID-19 patients without PE, suggesting that Ddimer levels can be used for diagnostics, prognostic purposes, and risk stratification. [29] [30] [31] In a study of moderate COVID-19, there was a lower incidence of PE (8.3%) and neither obesity nor diabetes were predisposing factors. 30 Patients who were treated with anticoagulation, either prophylactic or therapeutic dose, low molecular weight heparin or subcutaneous J o u r n a l P r e -p r o o f unfractionated heparin prior to or during hospitalization, had a significantly lower odds for developing PE. 30 Importantly, PE was more likely to develop in patients with delayed hospitalization. 30 Interestingly, in a study of all-comers on statins predating mild, moderate or severe COVID-19 illness, treatment resulted in a significantly lower odds ratio (OR) of PE; OR 0.4 [95%, CI 0.23-0.75]. 29 Thus, anticoagulation, statins, and modulating the intensity of the inflammatory response to COVID-19 may be helpful in avoiding PE in hospitalized individuals.

Multi-center inpatient studies show a 10-14.7% incidence of venous thromboembolism in COVID-19 illness compared to 0.1% of the general population, but up to as high as 45.4% in ICU-level patients. [32] [33] [34] [35] Many develop asymptomatic DVT. Some centers only screened symptomatic patients; thus, the incidence is likely underreported in those studies. Like pulmonary embolism, COVID-19 patients with DVT had higher D-dimer levels. 34-36 There were no differences in baseline sex, age, or BMI of COVID-19 patients who developed DVT as compared to those who did not, in limited studies. 34-36 Additionally, DVT was linked to worse multi-system organ function and breakthrough from prophylactic anticoagulation.

A large, single center, retrospective study of 362 patients found an incidence of total venous and arterial thromboembolic events of 7.7%, but this number may be underestimated as there was no surveillance of asymptomatic patients. 36 The majority of those diagnosed with DVT also had concomitant PE; non-survivors had higher D-dimer levels. 36 A prospective study of 156 COVID-19 positive inpatients evaluated the incidence of 35 There was no significant difference in obesity, sex, or age in patients who developed DVT versus those who did not. 35 The incidence of DVT appears higher in critically ill COVID-19 patients. 34 

The incidence of stroke in COVID-19 infection is approximately 1.7%. 37 By comparison, the risk of stroke in the general population is 0.2%. 38 Studies point to severe COVID-19 infection or underlying cardiovascular risk factors as highly contributory to stroke. 39, 40 In comparison to incident DVT and PE, there appears to be a stronger association of underlying cardiovascular disease (CVD) risk factors with COVID-19-associated stroke.

Retrospective case control studies have documented increased stroke in hospitalized COVID-19 patients, and conversely, more frequent COVID-19 infection in those hospitalized with stroke during the time frame of the pandemic. COVID-19 was more often associated with stroke in Black individuals in a larger, multicenter analysis. 39 41 Similar data from a single center retrospective study support the observation that severe COVID-19, hypertension and T2DM are associated with increased incidence of stroke, but in this study, age was a significant factor as well, with all strokes occurring in patients >60 years. 40 COVID-19 infected stroke patients have poorer outcomes and prolonged neurologic deficits, with worse neurologic disabilities at discharge and a higher incidence of delirium than stroke patients without COVID-19. 42

Acute mesenteric ischemia and mesenteric venous thrombosis are rare complications of COVID-19, thus, data are limited. 43-45 Clinicians should be vigilant for intestinal thrombotic injury in the correct context. In a case report, one patient presented with mesenteric venous thrombosis after presenting 20 days after the onset of COVID-19 with severe abdominal pain, suggesting prolonged hypercoagulability in some individuals. 45 

There is varying evidence on indications, dose, and efficacy of medical therapy for thrombotic complications of COVID-19. Studies suggest the greatest effect in preventing thrombotic injury is with heparins rather than direct oral anticoagulants (DOAC). [46] [47] [48] [49] It is important to note that many studies are non-randomized and focus on macrovascular rather than microvascular thrombosis.

Heparin has been studied in several randomized controlled clinical trials in non-critically and critically ill patients. 46, 47 Patients were randomized to either therapeutic doses of unfractionated heparin (UFH) or LMWH based on local dosing protocols or standard thromboprophylaxis. In non-critically ill patients, therapeutic heparin increased organ supportfree days, defined as the total number of days without respiratory or cardiovascular support, OR 1.27 (95% CI, 1.03-1.58). Patients on therapeutic heparin were less likely to die (OR 0.72 95% CI, 0.53-0.98). There was a non-statistically significant increase in bleeding (OR 1.8, 95% CI, 0.9-3.74). 46 By comparison, critically ill COVID-19 patients on therapeutic anticoagulation did not have a significant improvement in organ support-free days or mortality. Thrombosis and risk of major bleeding was similar between treatment assignments. 47 Thus, the optimal window for therapeutic anticoagulation may be early in the course of illness. Accordingly, in a retrospective study looking at incidence of PE in patients with COVID-19, non-ICU level COVID-19 individuals on prophylactic anticoagulation were found to have a lower incidence of PE later in the course of their illness. 30 DOACs have also been studied in patients with COVID-19. 48 In a large randomized control trial, patients were randomized to therapeutic or prophylactic doses. 48 Most received J o u r n a l P r e -p r o o f rivaroxaban; however, unstable patients received enoxaparin and were later switched to rivaroxaban once stable, while a minority received unfractionated heparin. There was no reduction in the duration of hospitalization or supplemental oxygen, DVT, PE, MI, stroke or death with therapeutic anticoagulation and there were no differences when stratifying for stability. Clinically significant bleeding events were more common in patients receiving therapeutic anticoagulation (8% vs. 2%, p = 0.001). 48 Another large multicenter retrospective study demonstrated benefit of anticoagulation with either warfarin or DOACs (dabigatran, rivaroxaban, or apixaban) predating COVID-19, supporting the hypothesis that early anticoagulation is most beneficial in preventing thrombosis during infection. 49 Patients in this study were older, more likely to have hypertension, T2DM, dyslipidemia, and cardiovascular risk factors; a high-risk group for developing prothrombotic complications of COVID-19. Patients who were on therapeutic oral anticoagulation at baseline had less ICU admission, RR 0.45 (95% CI, 0.32-0.62), and lower combined ICU admission and death, RR 0.72 (95% CI, 0.57-0.9), after adjustment. Anticoagulation after hospitalization did not significantly alter ICU admission or death in this observational cohort. 49 However, this finding is contradicted by a retrospective study of hospitalized patients receiving apixaban, enoxaparin, or heparin. 50 Patients on apixaban at prophylactic or therapeutic doses showed lower adjusted odds for death OR 0.46, (95% CI 0.30-0.71) and OR 0.57, (95% CI 0.38-0.85), respectively, as compared to patients who were not treated. In this study, neither prophylactic nor therapeutic doses of UFH were of benefit. Stratifying by D-dimer levels indicated that patients with low levels < 1 µg/mL did not benefit from anticoagulation therapy. However, patients with D-dimer > 1 µg/mL had lower mortality on either enoxaparin at prophylactic doses or apixaban at prophylactic or therapeutic doses. 50 J o u r n a l P r e -p r o o f A recent, multicenter, randomized controlled trial studied the use of antiplatelet and anticoagulation therapy in outpatients symptomatic from COVID-19. Patients were randomized into one of the following arms: aspirin 81 mg once daily, apixaban 2.5 mg twice daily (prophylactic dosage), apixaban 5mg twice daily (therapeutic dosage), or placebo. Patients were excluded if they were previously hospitalized with COVID-19, had other indications for anticoagulation, or had recent major bleeding events. 51 When compared to placebo, treatment with aspirin and apixaban showed no reduction in thrombotic events (DVT, PE, arterial thromboembolism, MI, and stroke). There was an increased risk of minor bleeding in patients receiving therapeutic apixaban with an increased risk difference of 6.9 (95% CI 1.4-12.9). 51 Anti-platelet agents, including aspirin, P2Y12 inhibitors, and dual anti-platelet therapy (DAPT) do not appear to be beneficial in preventing death or progression of COVID-19 in small retrospective studies. 52,53 A larger, retrospective, multicenter study showed that patients who received aspirin prior to hospitalization had lower mortality rates, ICU admission, and need for mechanical ventilation. 54 These patients were also more likely to have underlying medical comorbidities such as hypertension, coronary artery disease, and T2DM.

Current therapeutic guidelines to prevent prothrombotic complications of COVID-19 are limited by the lack of sufficient randomized control trials of various anticoagulation and antiplatelet regimens. Limited data from randomized trials suggest that early heparin anticoagulation, prior to progression to severe COVID -19, may decrease thrombotic complications and death. 30 

Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Review: Viral infections and mechanisms of thrombosis and bleeding

Mechanisms of thrombosis and cardiovascular complications in COVID-19

Endothelial cell infection and endotheliitis in COVID-19

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy

Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection

Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury

Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis

Thrombotic microangiopathy in a patient with COVID-19

Ocular Pathology and Occasionally Detectable Intraocular Severe Acute Respiratory Syndrome Coronavirus-2 RNA in Five Fatal Coronavirus Disease-19 Cases

Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study

Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Association Between COVID-19 Diagnosis and In-Hospital Mortality in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction

Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study

Pathological findings in the postmortem liver of patients with coronavirus disease 2019 (COVID-19)

Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data

Hyperthrombotic Milieu in COVID-19 Patients

Acute Pulmonary Embolism and COVID-19

Pulmonary embolism in COVID-19 patients: a French multicentre cohort study

Acute pulmonary embolism in COVID-19 disease: Preliminary report on seven patients

The epidemiology of venous thromboembolism

Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis

Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Stroke as a Neurological Complication of COVID-19: A Systematic Review and Meta-Analysis of Incidence, Outcomes and Predictors

Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort

Acute Ischemic Stroke and COVID-19: An Analysis of 27 676 Patients

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study

COVID-19 Coagulopathy with Superior Mesenteric Vein Thrombosis Complicated by an Ischaemic Bowel

Acute Intestinal Ischemia in a Patient with COVID-19 Infection

Subacute mesenteric venous thrombosis secondary to COVID-19: A late thrombotic complication in a nonsevere patient

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised

Anticoagulation in COVID-19: Effect of

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial

Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study

Antiplatelet therapy in patients with Covid-19: A retrospective observational study. Thrombosis Update

Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease

Incidence of Myocardial Injury in COVID-19-Infected Patients: A Systematic Review and Meta-Analysis